Cannabis users reported that it can reduce the symptoms of inflammatory bowel disease (IBD). Ultimately for the first time, this statement was proven by an experiment conducted in mice jointly by the University of Bath and the University of Massachusetts Medical School. The research findings were published in the Journal of Clinical Investigation.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis (UC).
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.